Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
Two Phase II Trials Display Ramucirumab Potential Efficacy
Gene Variant Associated With 44 Percent Cancer Risk Reduction
Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
HCT Survivors More Likely To Show Heart Disease Risk Factors
PV-10 Produces 51 Percent Response Rate in Phase II Trial
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Three Studies Test Oncotype DX In Breast and Colon Cancers
NCI-Approved CTEP Trials For the Month of October
FDA Approves Abraxane And Alimta for NSCLC
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Senate Finance Committee advances RFK Jr. to likely confirmation, with Bill Cassidy (R-LA) casting the deciding vote
- “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
